Replies to post #121087 on NanoViricides Inc. (NNVC)

[KMBJN]

Forgot to mention the most troubling thing from the 10-Q:

"Until last year, we were limited to performing R&D to develop drug candidates capable of further clinical development, but did not have the capability to produce the drug candidates in a suitable manner and quantities required for the studies to advance them into an IND stage and human clinical trials."

I somehow missed that memo. Maybe I misunderstood, or maybe the company thought they had the capability to advance into an IND but found out later they couldn't for some reason?

Maybe their plans really will work out this time. Potential is so big that am willing to give them another chance. Have not allocated any more capital here until further progress, though, showing they really can and will get a drug into clinical trials.

[Trendliner]

To answer your questions
1) Don't know why ES did not submit for IND approval
2) ES not stupid... just one of those lucky blokes who was born intelligent, good looking and charming and grew overconfident as a result. One can get pretty far on such God-given-gifts but there are limits and he's reached them
3) Dr. Vivian Boniuk was not biased by compensation as she got zero dollars and zero stock for the work. She took it on because viral infections of the eye had no other cure-candidate on the horizon.
4) Correct many drugs successful in animals fail in humans but those work on metabolic pathways. The mechanism of action for the nanoviricide is rather simple and works in the blood-stream. It does not involve the cells metabolism because its effect takes place before the virus enters the living cell and coopts its metabolic machinery.


You sound biased.